Silvio Danese, MD, PhD 

Measuring Patient Satisfaction with Inflammatory Bowel Disease Treatments and Communication Regarding Treatment Changes 

How do you evaluate patients’ satisfaction and expectations when providing care for UC and CD?

How do you discuss with patients the idea of escalating/switching therapy, perhaps in the absence of symptoms, and target something they may not feel?

Videos

Silvio Danese, MD, PhD; Bruce Sands, MD, and Jean-Frederic Colombel, MD, conclude by sharing their approaches to evaluating patient satisfaction and expectations when providing care for ulcerative colitis and Crohn's disease, while also touching upon the importance of discussing the potential need for escalating or switching therapies to better manage the underlying disease processes. 

Combination therapy in Inflammatory Bowel Disease

What is the current evidence on Advanced Combination Therapy for UC and CD? What are the benefits and challenges of this approach?

Medical experts in inflammatory bowel disease discuss the current evidence on dual advanced therapy for ulcerative colitis and Crohn's disease, highlighting the potential benefits, while also addressing the challenges and complexity of treatment management. 

Combination Therapy in Inflammatory Bowel Disease 

Considerations for Choosing Advanced Treatments and Setting Patient Expectations 

When do you consider starting or switching advanced treatment for UC and CD?

How do you communicate with the patient about starting an advanced treatment?

Gastroenterologist experts discuss the current landscape of biologic treatments for inflammatory bowel disease and the occasional necessity to switch between different biologic agents, while also sharing insights on their preferred treatment sequencing strategies. 

Unmet Needs and Starting Advanced Treatment in Inflammatory Bowel Disease 

When should clinicians start thinking about starting advanced targeted therapies for patients with UC or CD?

Silvio Danese, MD, PhD; Bruce Sands, MD, and Jean-Frederic Colombel, MD, highlight the common practice in many community settings of treating inflammatory bowel disease (IBD) with corticosteroids, with or without 5-aminosalicylic acid, and cycling patients through this regimen for prolonged periods, while emphasizing the significant impact and toxicities associated with this treatment approach. 

Silvio Danese, MD, PhD

Articles